InvestorsHub Logo
Followers 5
Posts 590
Boards Moderated 0
Alias Born 03/27/2019

Re: Sam81 post# 201180

Friday, 07/12/2019 7:15:02 AM

Friday, July 12, 2019 7:15:02 AM

Post# of 430271
Sam, as always, thank you! Question- Would your normalized scripts account for this- "Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $35.00 price target on Amarin Corporation (NASDAQ: AMRN) noting that sales for Vascepa may be under represented by scripts. Apparently, an increasing percentage of scripts are coming in as 90-day scripts while 30-day and 90-day scripts are both counted as one. "
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News